Nyrada Inc
ASX:NYR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nyrada Inc
Revenue
Nyrada Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nyrada Inc
ASX:NYR
|
Revenue
AU$2.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Revenue
AU$1.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$413m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$76.8m
|
CAGR 3-Years
69%
|
CAGR 5-Years
145%
|
CAGR 10-Years
44%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Revenue
AU$93.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
Nyrada Inc
Glance View
Nyrada, Inc. operates as a pre-clinical stage, drug development company. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.
See Also
What is Nyrada Inc's Revenue?
Revenue
2.5m
AUD
Based on the financial report for Dec 31, 2025, Nyrada Inc's Revenue amounts to 2.5m AUD.
What is Nyrada Inc's Revenue growth rate?
Revenue CAGR 5Y
17%
Over the last year, the Revenue growth was 38%. The average annual Revenue growth rates for Nyrada Inc have been 7% over the past three years , 17% over the past five years .
